CW March 2000
Volume 9Issue Number 3 March 2000 ISSN 10593802 RhEPO/NESP Offer More Convenient Dosing SchedulesHigher doses of rhEPO at less frequent intervals, or use of a new synthetic agent (NESP) for erythropoiesis support, offer quality of life advantages for patients receiving cancer treatment.
Go to Previous Page Go to Next Page Source & Additional Reading Based on Dr. Demetri?s presentation, "Novel strategies for erythropoietic stimulation in chronic diseases," at a satellite symposium preceding the 41st Annual Meeting of the American Society of Hematology, New Orleans. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW March 2000Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
